Intravitreal anti-VEGF therapy for neovascular age-related macular degeneration and the risk of stroke.

Hdl Handle:
http://hdl.handle.net/10147/136849
Title:
Intravitreal anti-VEGF therapy for neovascular age-related macular degeneration and the risk of stroke.
Authors:
Cleary, C A; Sharaznayan, D; Hickey-Dwyer, M
Affiliation:
Department of Ophthalmology, Mid-Western Regional Hospital, Dooradoyle, Limerick. ucclearly@yahoo.com
Citation:
Intravitreal anti-VEGF therapy for neovascular age-related macular degeneration and the risk of stroke. 2011, 104 (5):146-9 Ir Med J
Journal:
Irish medical journal
Issue Date:
May-2011
URI:
http://hdl.handle.net/10147/136849
PubMed ID:
21736091
Additional Links:
http://www.ncbi.nlm.nih.gov/pubmed/21736091
Abstract:
The purpose of this study was to compare the vascular event rate in AMD patients treated with an intravitreal VEGF inhibitor with a historical control group treated with photodynamic therapy. We reviewed medical records of 83 patients treated with intravitreal anti-VEGF for AMD between 2005-2007, and 60 patients treated with PDT between 2001-2004. Mean follow-up in the anti-VEGF group was 40 months versus 95 months in the PDT group. Mean age (76 +/- 9 years, versus 74 +/- 10 years, p=n.s.) and cardiovascular risk factor profile were similar. Vascular event rates in each group were 2.6 per 100 patient years versus 2.3 per 100 patient years, (p = n.s). Age over 80 years was associated with an increased risk of a vascular event (odds ratio = 1.113, p<0.05). Despite the high prevalence of risk factors in AMD patients, the incidence of vascular events was low and associated with older age rather than therapy received.
Item Type:
Article
Language:
en
ISSN:
0332-3102

Full metadata record

DC FieldValue Language
dc.contributor.authorCleary, C Aen
dc.contributor.authorSharaznayan, Den
dc.contributor.authorHickey-Dwyer, Men
dc.date.accessioned2011-07-25T13:21:35Z-
dc.date.available2011-07-25T13:21:35Z-
dc.date.issued2011-05-
dc.identifier.citationIntravitreal anti-VEGF therapy for neovascular age-related macular degeneration and the risk of stroke. 2011, 104 (5):146-9 Ir Med Jen
dc.identifier.issn0332-3102-
dc.identifier.pmid21736091-
dc.identifier.urihttp://hdl.handle.net/10147/136849-
dc.description.abstractThe purpose of this study was to compare the vascular event rate in AMD patients treated with an intravitreal VEGF inhibitor with a historical control group treated with photodynamic therapy. We reviewed medical records of 83 patients treated with intravitreal anti-VEGF for AMD between 2005-2007, and 60 patients treated with PDT between 2001-2004. Mean follow-up in the anti-VEGF group was 40 months versus 95 months in the PDT group. Mean age (76 +/- 9 years, versus 74 +/- 10 years, p=n.s.) and cardiovascular risk factor profile were similar. Vascular event rates in each group were 2.6 per 100 patient years versus 2.3 per 100 patient years, (p = n.s). Age over 80 years was associated with an increased risk of a vascular event (odds ratio = 1.113, p<0.05). Despite the high prevalence of risk factors in AMD patients, the incidence of vascular events was low and associated with older age rather than therapy received.-
dc.language.isoenen
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/21736091en
dc.titleIntravitreal anti-VEGF therapy for neovascular age-related macular degeneration and the risk of stroke.en
dc.typeArticleen
dc.contributor.departmentDepartment of Ophthalmology, Mid-Western Regional Hospital, Dooradoyle, Limerick. ucclearly@yahoo.comen
dc.identifier.journalIrish medical journalen
dc.description.provinceMunster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.